Vasileios Askoxylakis, Vice President Experimental Medicine Oncology at Boehringer Ingelheim, shared a post on LinkedIn:
“I am excited to share that I have joined Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health!
It is a great privilege to be part of a large organization with such a steadfast commitment to patients and a culture that fosters innovation and collaboration. I look forward to partnering with and learning from outstanding colleagues and world-class leaders who bring immense acumen and deep expertise to drug development and R&D. I’m eager to contribute to the advancement of our oncology early clinical pipeline and the translation of cutting-edge science into meaningful therapies.”
